Development and Verification of an Immune-Based Gene Signature for Risk Stratification and Immunotherapeutic Efficacy Assessment in Gastric Cancer

Figure 3

External validation of the immune-related prognostic signature for gastric cancer. (a) Ranking of risk scores and (b) survival status for patients in the GSE66229 dataset. (c) Kaplan-Meier curves for OS between the high- and low-risk groups in the GSE66229 dataset. (d) ROCs for one year, three years, and five years in the GSE66229 dataset. (e) Univariate and (f) multivariate Cox regression analyses of the risk score and other clinical characteristics in the GSE66229 dataset. (g) Ranking of risk scores and (h) survival status for patients in the Imvigor210 dataset. (i) Kaplan-Meier curves for OS between the high- and low-risk groups in the Imvigor210 dataset.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)